Back to Results

NervGen Pharma Corp (NGEN)

Featured in Overvalued Stocks

NervGen Pharma Corp. is a healthcare company focused on biotechnology research and development. The company works on discovering, developing, and commercializing pharmaceutical treatments aimed at supporting nervous system repair in cases of neurotrauma and neurologic disease. Its lead candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial for spinal cord injury, stroke, multiple sclerosis, and Alzheimer’s disease. NervGen is also advancing NVG-300, which is in preclinical work for ischemic stroke and a confirmatory spinal cord injury study. The company has a licensing agreement with Case Western Reserve University covering patented technology with potential therapeutic applications for spinal cord injury and other nerve-damage-related conditions. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada. Its common stock is listed on the NASDAQ exchange under the symbol NGEN.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-NGEN
$1.46
-19.0% Downside
Overvalued
$10.60
489.1% Upside
Bargain
Weak
—
—
—
0.0%
August 12, 2026
-6.5x
48.8x
—
183.7 M
182.3 M
0.0%
88.6%
-27.2
—
56.4%
Send a message
Valuation • Fair Value

NervGen Pharma Corp (NASDAQ-NGEN) Fair Value by Valuation Model

Compare the primary fair value estimate for NervGen Pharma Corp (NASDAQ-NGEN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.46

Estimated downside of 19.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.41

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.48

Comparable-company valuation reference.

Analyst Price Target

$10.60

Analysts imply upside of 489.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for NervGen Pharma Corp (NASDAQ-NGEN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for NervGen Pharma Corp (NASDAQ-NGEN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-19.06 M

Current operating profitability reference.

EBITDA Forecast

-27.097 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review NervGen Pharma Corp (NASDAQ-NGEN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for NervGen Pharma Corp (NASDAQ-NGEN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-27.2

Lower score that deserves closer risk review.

FCF / Net Income

56.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for NervGen Pharma Corp (NASDAQ-NGEN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for NervGen Pharma Corp (NASDAQ-NGEN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for NervGen Pharma Corp (NASDAQ-NGEN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

NervGen Pharma Corp (NASDAQ-NGEN) Stock Forecast & Technical Outlook

Review NervGen Pharma Corp (NASDAQ-NGEN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for NervGen Pharma Corp (NASDAQ-NGEN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for NervGen Pharma Corp (NASDAQ-NGEN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for NervGen Pharma Corp (NASDAQ-NGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for NervGen Pharma Corp (NASDAQ-NGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for NervGen Pharma Corp (NASDAQ-NGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for NervGen Pharma Corp (NASDAQ-NGEN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, NervGen Pharma Corp (NASDAQ-NGEN) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

NervGen Pharma Corp (NASDAQ-NGEN) Stock FAQ

Quick answers about NervGen Pharma Corp (NASDAQ-NGEN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.46
Estimated downside 19.0%
Valuation Rating
Overvalued
Estimated downside of 19.0%
Analyst Target
$10.60
Implied upside 489.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for NervGen Pharma Corp (NASDAQ-NGEN) is $1.46. This implies an estimated downside of 19.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 19.0% versus the current market price.

The available analyst price target for NervGen Pharma Corp (NASDAQ-NGEN) is $10.60. The analyst target implies estimated upside of 489.1%.

The current financial health read for NervGen Pharma Corp (NASDAQ-NGEN) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for NervGen Pharma Corp (NASDAQ-NGEN) is August 12, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for NervGen Pharma Corp (NASDAQ-NGEN) is -6.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for NervGen Pharma Corp is 183.7 M.

The current enterprise value listed for NervGen Pharma Corp is 182.3 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for NervGen Pharma Corp is NASDAQ-NGEN, and the stock is listed on NASDAQ.

NervGen Pharma Corp (NASDAQ-NGEN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for NervGen Pharma Corp is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for NervGen Pharma Corp is 88.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)